CN109963570A - 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 - Google Patents

芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 Download PDF

Info

Publication number
CN109963570A
CN109963570A CN201780069179.8A CN201780069179A CN109963570A CN 109963570 A CN109963570 A CN 109963570A CN 201780069179 A CN201780069179 A CN 201780069179A CN 109963570 A CN109963570 A CN 109963570A
Authority
CN
China
Prior art keywords
drug
application
paeoniflorin
group
sjogren syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780069179.8A
Other languages
English (en)
Inventor
魏伟
吴华勋
顾芳
徐军
谢宏伟
徐广�
付劼
王学政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGZHOU HANFANG PHARMACEUTICAL Co.,Ltd.
Original Assignee
Ningbo Zhiming Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Zhiming Biotechnology Co ltd filed Critical Ningbo Zhiming Biotechnology Co ltd
Publication of CN109963570A publication Critical patent/CN109963570A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

芍药苷‑6'‑O‑苯磺酸酯在治疗干燥综合征的药物中的应用，芍药苷‑6'‑O‑苯磺酸酯的分子式为C29H32O13S。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780069179.8A 2017-01-21 2017-02-14 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 Pending CN109963570A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017071998 2017-01-21
CNPCT/CN2017/071998 2017-01-21
PCT/CN2017/073540 WO2018133139A1 (zh) 2017-01-21 2017-02-14 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用

Publications (1)

Publication Number Publication Date
CN109963570A true CN109963570A (zh) 2019-07-02

Family

ID=62907661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069179.8A Pending CN109963570A (zh) 2017-01-21 2017-02-14 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用

Country Status (6)

Country Link
US (2) US20180325931A1 (zh)
EP (1) EP3533451B1 (zh)
JP (1) JP6827113B2 (zh)
CN (1) CN109963570A (zh)
AU (1) AU2017394032B8 (zh)
WO (1) WO2018133139A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125818A1 (zh) * 2021-12-30 2023-07-06 广州白云山汉方现代药业有限公司 去苯甲酰芍药苷-6'-o-苯磺酸酯、及其制备方法与用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
CN115677789A (zh) * 2021-07-23 2023-02-03 广州白云山汉方现代药业有限公司 一种芍药苷-6-o′-苯磺酸酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603827A (zh) * 2012-02-10 2012-07-25 魏伟 一种芍药苷芳香族酯衍生物、其制备方法及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003304172A1 (en) * 2003-05-30 2005-01-04 Shen Zhen Lansen Medicine Co. Ltd. The pharmaceutical use of total glucide of peony
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2007092939A2 (en) 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
CA3009680C (en) 2006-03-16 2023-08-15 Symthera Canada Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
LT2126054T (lt) 2007-01-31 2016-10-10 Yeda Research And Development Company Limited Peradresuotos, genetiškai modifikuotos t reguliavimo ląstelės ir jų naudojimas autoimuninės ir uždegiminės ligos slopinimui
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
CA2740077A1 (en) 2008-10-08 2010-04-15 Cambridge Enterprise Limited Methods and compositions for diagnosis and treatment
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
EP2640420B1 (en) 2010-11-19 2018-08-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
CA2903737C (en) 2013-03-06 2021-05-18 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9394349B2 (en) 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
WO2015058214A1 (en) 2013-10-18 2015-04-23 Trustees Of The University Of Pennsylvania Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells
CR20160268A (es) 2013-12-20 2016-08-16 Gilead Sciences Inc Inhibidores de la quinasa reguladora de la señal de apoptosis
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2015109245A1 (en) 2014-01-17 2015-07-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus
WO2015107140A1 (en) 2014-01-17 2015-07-23 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Liposome-based immunotherapy
JP2017505766A (ja) 2014-01-17 2017-02-23 デベヴェ・テクノロジーズ 皮膚上でのイムノリバランス
US10130650B2 (en) 2014-01-27 2018-11-20 The Children's Hospital Of Philadelphia Compositions and methods for treating autoimmune and inflammatory diseases
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
WO2015123493A2 (en) 2014-02-13 2015-08-20 Northwestern University Compositions and methods for modulatuion of immune response
US10022443B2 (en) 2014-04-08 2018-07-17 Boston Pharmaceuticals Inc. Antibodies specific for IL-21 and uses thereof
US10308703B2 (en) 2014-04-28 2019-06-04 The National Institute For Biotechnology I Variants of DR3 and use thereof
KR101705446B1 (ko) 2014-04-29 2017-02-09 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
RS64542B1 (sr) 2014-04-30 2023-09-29 Hanall Biopharma Co Ltd Vezivanje antitela za fcrn za lečenje autoimunih bolesti
JP2017516853A (ja) 2014-05-23 2017-06-22 ミングサイト ファーマシューティカルズ，インク． 自己免疫性疾患の処置
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
DK3151853T3 (da) 2014-06-04 2020-07-27 Diamyd Medical Ab Glutaminsyre-decarboxylase (GAD) til anvendelse ved behandling af en autoimmun sygdom
SG10201903578VA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
CN107921104A (zh) 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
US20160333409A1 (en) 2015-03-09 2016-11-17 Cb Biotechnologies, Inc. Method for identifying disease-associated cdr3 patterns in an immune repertoire
KR20160126734A (ko) 2015-04-24 2016-11-02 한국생명공학연구원 자가면역질환 환자 특이적 유도만능줄기세포의 제조방법 및 이의 이용
US20180142211A1 (en) 2015-05-20 2018-05-24 Biokine Therapeutics Ltd Methods of mesenchymal stem cell mobilization and expansion
PL3297992T3 (pl) 2015-05-22 2020-07-27 Chong Kun Dang Pharmaceutical Corp. Heterocykloalkilowe związki pochodne jako selektywne inhibitory deacetylazy histonowej oraz zawierające je kompozycje farmaceutyczne
WO2016191545A1 (en) 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
US20180116988A1 (en) 2015-05-28 2018-05-03 The Regents Of The University Of Colorado A Body Corporate Methods of preventing and treating autoimmunity
WO2016196393A2 (en) 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
JP6786526B2 (ja) 2015-06-03 2020-11-18 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 改変されたｃｃｌ２０ロックド二量体ポリペプチド
US20160355464A1 (en) 2015-06-07 2016-12-08 Mark Quang Nguyen Fumarate compounds, pharmaceutical compositions thereof, and methods of use
WO2016200694A1 (en) 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
JP2018522833A (ja) 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療
WO2016204429A1 (ko) 2015-06-18 2016-12-22 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물.
RU2601410C1 (ru) 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603827A (zh) * 2012-02-10 2012-07-25 魏伟 一种芍药苷芳香族酯衍生物、其制备方法及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
于静雅: "芍药苷对原发性干燥综合征患者外周血单个核细胞表面 P2X7R 表达及炎症细胞因子 IL-1、 IL-6 分泌的干预作用", 《万方学术期刊数据库 硕士学位论文》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125818A1 (zh) * 2021-12-30 2023-07-06 广州白云山汉方现代药业有限公司 去苯甲酰芍药苷-6'-o-苯磺酸酯、及其制备方法与用途

Also Published As

Publication number Publication date
AU2017394032A1 (en) 2019-06-13
JP2019537615A (ja) 2019-12-26
WO2018133139A1 (zh) 2018-07-26
AU2017394032A8 (en) 2020-10-22
EP3533451A4 (en) 2020-01-15
EP3533451B1 (en) 2022-07-27
US20200147116A1 (en) 2020-05-14
AU2017394032B2 (en) 2020-10-08
JP6827113B2 (ja) 2021-02-10
US20180325931A1 (en) 2018-11-15
AU2017394032B8 (en) 2020-10-22
EP3533451A1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
US10201537B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US20160022684A1 (en) Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
US20080032989A1 (en) Method of treating inflammatory diseases using tyroskine kinase inhibitors
CN109963570A (zh) 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
TW201628622A (zh) Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
Zhang et al. Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects
CN102895661A (zh) 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
KR19990044834A (ko) 네가티브인자작용 억제제
US11197860B2 (en) Treatment of primary biliary cholangitis and primary sclerosing cholangitis with baricitinib
Song et al. Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets
WO2018081090A1 (en) Compositions and methods for the treatment of hbv infection
CN101048160B (zh) 嘌呤和嘧啶cdk抑制剂及其在制备用于治疗自身免疫性疾病的药物中的用途
JP2018534309A (ja) 自己免疫疾患の処置
CN101747414B (zh) TNF-α结合肽和TNFR1封闭肽及其在治疗TNF相关疾病中的应用
US7875616B2 (en) Use of tyrosine kinase inhibitor to treat diabetes
CN109568430A (zh) 一种免疫增强剂的制备方法和应用
Friedlaender et al. Effect of cortisone administered orally in bronchial asthma
CN104825455B (zh) 依鲁替尼的用途
CN104411309A (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
CN1333044A (zh) 消渴降糖宝
RU2635968C1 (ru) Способ лечения и профилактики состояний аллергического спектра
CN102321155A (zh) Tnf结合肽和tnfr1封闭肽及其在治疗溃疡性结肠炎中的应用
Miao Clinical Efficacy of Lenalidomide Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma
CN116672367A (zh) 鱼油在制备治疗荨麻疹药物的应用及其药物组合物
CN104069097A (zh) 去甲斑蝥素用于治疗类风湿关节炎的新用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201117

Address after: 510970 No.8, Wenquan Avenue, Conghua, Guangzhou, Guangdong Province

Applicant after: GUANGZHOU HANFANG PHARMACEUTICAL Co.,Ltd.

Address before: 315194 Li Bing, Room 204, 2nd Floor, D Building, 655 Xueshi Road, Yinzhou District, Ningbo City, Zhejiang Province

Applicant before: Ningbo Zhiming Biotechnology Co.,Ltd.

Applicant before: Wei Wei